| |
Control (n = 10)
|
Acarbose (n = 10)
|
Nateglinide (n = 10)
|
|---|
| |
Baseline
|
12 weeks
|
Baseline
|
12 weeks
|
Baseline
|
12 weeks
|
|---|
|
Age (years)
|
68.0 ± 7.7
| |
67.6 ± 6.2
| |
67.8+/-8.6
| |
|
Male gender (%)
|
5 (50)
| |
7 (70)
| |
7 (70)
| |
|
BMI (kg/m2)
|
26.8 ± 3.2
|
26.1 ± 3.4
|
25.8 ± 2.5
|
25.3 ± 7.4
|
25.8 ± 3.3
|
25.5 ± 2.9
|
|
Total cholesterol (mg/dl)
|
213.2 ± 15.9
|
210.2 ± 23.2
|
201.8 ± 25.4
|
205.7 ± 38.1
|
206.0 ± 25.4
|
211.1 ± 29.6
|
|
Triglyceride (mg/dl)
|
132.4 ± 13.1
|
127.7 ± 17.1
|
116.1 ± 20.8
|
125.5 ± 34.7
|
121.7 ± 19.3
|
121.6 ± 22.3
|
|
HDL cholesterol (mg/dl)
|
53.8 ± 11.0
|
53.7 ± 9.5
|
56.2 ± 11.0
|
52.7 ± 14.4
|
54.4 ± 12.5
|
57.4 ± 13.2
|
|
LDL cholesterol (mg/dl)
|
135.0 ± 48.8
|
143.9 ± 52.7
|
141.6 ± 69.3
|
137.4 ± 77.3
|
149.4 ± 76.0
|
121.6 ± 22.3
|
|
HbA1c (%)
|
5.8 ± 0.6
|
5.6 ± 0.5
|
6.0 ± 0.3
|
5.9 ± 0.4
|
6.1 ± 0.6
|
5.8 ± 0.4
|
|
Fasting glucose (mg/dl)
|
110.7 ± 15.0
|
109.3 ± 12.0
|
109.6 ± 17.5
|
108.8 ± 15.7
|
119.6 ± 17.5
|
110.4 ± 11.1
|
|
Fasting insulin (μU/ml)
|
7.5 ± 2.9
|
7.2 ± 2.8
|
9.6 ± 5.6
|
10.6 ± 6.8
|
6.6 ± 4.1
|
6.5 ± 2.7
|
|
HOMA-IR
|
2.0 ± 0.7
|
1.9 ± 1.8
|
2.6 ± 1.6
|
2.8 ± 1.9
|
2.0 ± 1.6
|
1.8 ± 0.7
|
|
Systolic BP (mmHg)
|
143.5 ± 28.5
|
145.5 ± 38.2
|
141.1 ± 26.1
|
142.6 ± 19.1
|
141.3 ± 28.5
|
143.8 ± 23.5
|
|
Diastolic BP (mmHg)
|
89.1 ± 19.2
|
89.3 ± 11.9
|
88.1 ± 23.1
|
83.1 ± 38.9
|
88.3 ± 11.9
|
89.1 ± 23.8
|
|
Heart rate (beats/min)
|
68.8 ± 9.8
|
68.8 ± 8.9
|
69.2 ± 11.1
|
62.9 ± 11.2
|
68.2 ± 8.9
|
68.9 ± 8.2
|
- Data are shown as mean ± SD. BMI, body mass index; HDL, High-density lipoprotein; LDL, Low-density lipoprotein; HbA1c, glycohemoglobin A1c; HOMA-IR, insulin resistance by homeostasis model assessment; BP, blood pressure.
